Welcome to our dedicated page for 20/20 Biolabs news (Ticker: AIDX), a resource for investors and traders seeking the latest updates and insights on 20/20 Biolabs stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 20/20 Biolabs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 20/20 Biolabs's position in the market.
20/20 BioLabs (Nasdaq: AIDX) reported FY2025 revenue of $2.0 million, up 17% year-over-year, with gross profit $0.6M (+68%) and gross margin expanding 900 basis points to 29.6%. Operating expenses fell 35% to $3.9M and net loss improved to ($3.7M).
The company completed a $5.0M private placement on February 19, 2026, secured $520,000 in Maryland state funding for firefighter screenings, launched OneTest for Longevity with IBM AI support, licensed ROKIT CKD technology, and began Nasdaq trading under AIDX.
20/20 BioLabs (Nasdaq: AIDX) announced that 18 Maryland fire department groups will receive over $520,000 from the Maryland Department of Health to fund its OneTest™ multi-cancer early detection blood test.
Testing of an estimated 1,400+ firefighters is expected in April–May 2026, a ~225% increase in funded MCEDs versus last year.
20/20 BioLabs (Nasdaq: AIDX) entered an exclusive U.S. license and access agreement with ROKIT Healthcare to integrate ROKIT’s proprietary chronic kidney disease (CKD) prediction algorithm into 20/20’s Longevity Platform, adding CKD risk assessment to its OneTest for Longevity offering.
Under the deal, ROKIT will reimburse one-third of mutually agreed sales and marketing expenses and receive a running royalty on net sales; the parties also anticipate negotiating separate exclusive commercialization rights for Korea and possibly other East Asian markets. The integration targets earlier CKD detection and enhanced biomarker-driven decision support for patients and providers.
20/20 BioLabs (Nasdaq: AIDX) outlines advantages of its patented protein tumor marker (PTM) approach for multi-cancer early detection, citing May–Nov 2025 validation studies showing up to 50% sensitivity for some early-stage tumors and a blinded MD Anderson study reporting ~90% early-stage lung cancer detection.
The company advocates a tiered screening model using protein-based OneTest first, then ctDNA or imaging, and notes a Feb 2026 Medicare coverage pathway beginning in 2028.
20/20 BioLabs (Nasdaq: AIDX) launched OneTest for Longevity, a commercial blood-test solution available Feb 25, 2026 that combines inflammatory biomarkers, dietary and lifestyle inputs, and curated research to estimate chronic disease risk and offer personalized dietary guidance.
The platform uses IBM watsonx.ai and IBM Granite 4.0 foundation models, with Docling reportedly processing nutritional research 30x faster. The test is offered as a laboratory-developed test (LDT) in CLIA-licensed, CAP-accredited labs and has not sought or received FDA approval.